The Ministry of Health has approved a medicine for corona patients in a mild-moderate condition
The antiviral drug Molnofiravir was approved by the FDA last week and is also expected to help those infected with the Omicron strain.
It will be given in tablets to patients over 18 with at least one risk factor for deterioration in hospitalization or mortality.
It will be taken for up to five days from the onset of the first symptoms
Meirav Cohen
02/01/2022
Sunday, 02 January 2022, 16:10 Updated: 16:39
Share on Facebook
Share on WhatsApp
Share on Twitter
Share on Email
Share on general
Comments
Comments
In the video: Bennett refers at the cabinet meeting to an increase in morbidity data in Corona (Photo: GPO)
The Ministry of Health today (Sunday) approved MSD's antiviral drug MSN to treat corona, according to the Corona virus' headquarters.
This is against the background of the sharp rise in coronary heart disease in Israel in light of the spread of the Omicron strain.
The Ministry of Health's approval came after the drug was approved last week in an emergency approval by the FDA, and it is expected to arrive in Israel in the coming days.
Its mechanism of action, designed to create errors in the genetic code of the virus and thus prevent its further replication, is not expected to be affected by the variant type of the corona virus, and is therefore also relevant in view of the spread of the omicron variant.
More on Walla!
Thousands of packets on the way: what's important to know about Pfizer's drug to Corona
To the full article
More on Walla!
The FDA has given emergency approval for Pfizer's pill against Corona
Reduce hospitalizations and mortality: A new drug for Corona gives hope to fight the virus
A smart test detects an increased risk of stroke - now in a special operation
Queue for corona tests outside the Ariella house in Tel Aviv, today (Photo: Reuven Castro)
Molnofiravir is an antiviral drug given in tablets.
The drug is intended to be given to corona patients with mild to moderate symptoms who have at least one risk factor for deterioration in hospitalization or mortality, when other existing and approved treatment alternatives in Israel are not suitable for them.
The drug, which is intended for people aged 18 and over, is given in pills and is intended for home treatment.
It should be given three to five days from the onset of symptoms.
The study found that the drug reduced hospitalizations and mortality by about 30% of the subjects, and its side effects observed in the study were moderate and similar between the treatment group and the placebo group.
news
Corona
Tags
Corona
Omicron variant